Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Cancidas opvejer risiciene ved behandling af invasiv kandidose eller invasiv aspergillose og empirisk behandling af formodede svampeinfektioner hos voksne og eller pædiatriske patienter.
The Committee for Medicinal Products for Human Use (CHMP) decided that Cancidas’ s benefits are greater than its risks for the treatment of invasive candidiasis or aspergillosis, and empirical therapy for presumed fungal infections, in adult or paediatric patients.